II Ivivi Technologies, Inc.

Proprietary Pulsed Electromagnetic Field (PEMF) technology, developed by Ivivi Technologies, Inc. (AMEX:II), improved neuron survival in a standard animal cell model of brain inflammation, researchers reported today in a platform presentation at the Bioelectromagnetics Society (BEMS, http://www.bioelectromagnetics.org) Annual Meeting, in Kanazawa, Japan. Inflammation is associated with neuron death that occurs in Parkinson�s disease and other neurodegenerative conditions in humans. The preliminary data, from studies conducted by Dr. Diana Casper, neurobiologist at Albert Einstein College of Medicine (NY), indicates that certain PEMF therapies could be neuroprotective. �Dopaminergic neurons, which die in Parkinson�s disease, are clearly susceptible to inflammation,� said Dr. Diana Casper. �If we could keep sufficient numbers of them alive, we possibly could keep patients from exhibiting the symptoms associated with Parkinson�s. In this model, PEMF signals appeared to both reduce levels of inflammation as well as protect neurons from inflammatory effects.� �Dr. Casper�s work demonstrated that our PEMF signals doubled neuron survival in cultures that were subjected to inflammation-creating chemical insult,� commented Sean Hagberg, Ph.D., Chief Science Officer, Ivivi Technologies. �While the primary pathological events in neurodegenerative conditions such as Parkinson�s disease are still unknown, the potential to delay or prevent the death of dopaminergic neurons could provide new opportunities for Ivivi.� Andre� DiMino, Co-CEO, Ivivi Technologies noted, �This neurological study confirms our commitment to develop innovative, non-invasive and non-pharmacologic electrotherapies, targeting fundamental disease processes common to many of the most debilitating and challenging illnesses. Our mission is to expand applications of our proprietary electrotherapeutic technologies as we intend to continue to develop our technology for this and other areas.� About Ivivi Technologies, Inc. Based in Northvale, NJ, Ivivi Technologies, Inc. is a medical technology company focusing on designing, developing and commercializing its proprietary electrotherapeutic technology platform. Ivivi�s research and development activities are focused specifically on pulsed electromagnetic field, or PEMF, technology, which, by creating a therapeutic electrical current in injured soft tissue, stimulates biochemical and physiological healing processes to help repair the injured tissue and reduce related pain and inflammation. The Company�s Electroceuticals� have been used in non-invasive treatments for a wide array of conditions, including chronic wounds, pain and edema following plastic and reconstructive surgery and chronic inflammatory disorders. Forward-Looking Statements This release contains "forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including the statements related to the preliminary data discussed above. Forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, the Company�s limited operating history, history of significant and continued operating losses and substantial accumulated earnings deficit, difficulties with its financial accounting controls, the failure of the market for the Company�s products to continue to develop, the inability for customers to receive third party reimbursement, the inability to obtain additional capital, the inability to protect the Company�s intellectual property, the loss of any executive officers or key personnel or consultants, competition, changes in the regulatory landscape or the imposition of regulations that affect the Company�s products and other risks detailed from time to time in the Company�s filings with the Securities and Exchange Commission, including the Company�s registration statement on Form SB-2. The Company assumes no obligation to update the information contained in this press release.